Search

everythinglearnresearchcommunity

for

Search:↓

Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.

Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.

Researchers developed a new skin patch that delivers more finasteride into the skin, potentially improving treatment for hair loss and prostate issues.

The CDC reports 23 measles cases in unvaccinated US kids, new treatments for eosinophilic esophagitis and osteopenia are approved, poor sleep may cause migraines, atopic dermatitis could lead to asthma, migraines might increase Crohn's disease risk, cancer may raise heart disease risk, gout is linked to prostate issues, Cabo Verde is malaria-free, social factors and vitamin D affect dementia risk, smoking increases hair loss risk, certain drugs might lower thyroid disease risk in arthritis, noma is a neglected disease, and meal timing could impact heart health.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

A new method was developed to make finasteride for treating hair loss.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

A new compound that could treat various androgen-related conditions was created and analyzed.

A new compound was made that might help treat diseases related to male hormones.

SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.

Finasteride works best in 6 months and lasts 6 years.

Finasteride effectively treats BPH but requires continuous use to maintain benefits.

Dutasteride is more effective than finasteride for treating BPH without extra safety risks.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Methylation in specific gene region causes finasteride resistance in some BPH patients.

Finasteride does not prevent bladder cancer.

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.

Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.